BURLINGTON - Azenta, Inc. (NASDAQ:AZTA), a leader in life sciences solutions, announced today that CEO Dr. Stephen Schwartz will retire after more than a decade at the helm. The company has commenced a search for his successor with the aid of executive search firm Heidrick & Struggles (NASDAQ:HSII).
Dr. Schwartz, who joined Azenta in April 2010 and took on the role of CEO in August 2010, will continue to lead the company until a new CEO is appointed. His leadership is credited with transforming Azenta from a semiconductor capital equipment company, formerly known as Brooks Automation (NASDAQ:AZTA), into a standalone life sciences entity with over $600 million in annual revenue and a global workforce exceeding 3,000.
Frank E. Casal, Chair of the Board, expressed the Board's gratitude for Dr. Schwartz's dedication and impact on Azenta's growth and transformation. The company's successful shift to a pure-play life sciences company and the sale of its Semiconductor Solutions business for $3 billion to Thomas H. Lee Partners are among the significant milestones during Dr. Schwartz's tenure.
The announcement coincides with Azenta's second-quarter earnings report for fiscal 2024. The company, which provides comprehensive solutions for drug development, clinical research, and advanced cell therapies, operates under industry-leading brands such as GENEWIZ and FluidX.
Azenta's headquarters are located in Burlington (NYSE:BURL), MA, with additional operations spread across North America, Europe, and Asia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.